文献速递认知障碍与痴呆

阿尔茨海默病风险个体的认知与神经影像特征及脑β-淀粉样蛋白沉积(INSIGHT-preAD):一项纵向观察性研究

Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
PubMed 文献 · Lancet Neurol · 2018-02-27

INSIGHT-preAD为法国Salpêtrière医院单中心纵向观察研究,纳入318例70-85岁主观记忆主诉但认知正常者,按基线18F-florbetapir PET淀粉样蛋白沉积阳性(88例)或阴性分层。淀粉样蛋白阳性组与阴性组在30个月时MMSE和CDR评分无显著差异;仅4例(均为淀粉样蛋白阳性)进展为前驱期阿尔茨海默病。

要点

  • 淀粉样蛋白阳性组APOE ε4携带者比例高于阴性组(38% vs 13%,p<0.0001)。
  • 30个月时淀粉样蛋白阳性与阴性组MMSE评分无显著差异(28.3 vs 28.9,p=0.16)。
  • 仅脑β-淀粉样蛋白沉积本身未预测30个月内进展为前驱期阿尔茨海默病。

核心结论

  • 仅脑β-淀粉样蛋白沉积本身未预测30个月内进展为前驱期阿尔茨海默病,需更长随访以确定该发现是否一致。

研究设计与样本

  • INSIGHT-preAD为正在进行的单中心观察性研究,地点为法国巴黎Salpêtrière医院。
  • 纳入70-85岁有主观记忆主诉但认知和记忆未受损者,要求MMSE评分≥27、临床痴呆评定量表评分0、FCSRT总回忆评分≥41。
  • 2013年5月25日至2015年1月20日共纳入318例参与者,平均年龄76.0岁(SD 3.5)。
  • 按基线18F-florbetapir PET脑β-淀粉样蛋白沉积阳性或阴性分层,88例(28%)为阳性。
  • 随访包括每6个月临床、认知和心理行为评估,每12个月神经心理评估、EEG和活动记录,每24个月MRI及18F-FDG和18F-florbetapir PET。

主要发现

  • 淀粉样蛋白β阳性组APOE ε4携带者多于阴性组(33例[38%] vs 29例[13%],p<0.0001)。
  • 校正年龄、性别和教育水平后,淀粉样蛋白β亚组在任何心理行为、认知、活动记录及结构和功能神经影像结果上均无差异。
  • 基线脑脊液β-淀粉样蛋白1-42浓度与平均18F-florbetapir摄取显著相关(r=-0.62,p<0.0001),与β-淀粉样蛋白1-42/1-40比值也显著相关(r=-0.61,p<0.0001)。
  • 脑脊液β-淀粉样蛋白1-42浓度识别淀粉样蛋白β沉积状态的AUC为0.89(95%CI 0.80-0.98),β-淀粉样蛋白1-42/1-40比值的AUC为0.84(95%CI 0.72-0.96)。
  • 30个月时(n=274),淀粉样蛋白β阳性与阴性组MMSE评分无显著差异(28.3[SD 2.0] vs 28.9[1.2],p=0.16),CDR评分也无显著差异(0.06[0.2] vs 0.05[0.3],p=0.79)。

关键数值与推荐

  • 前驱期阿尔茨海默病定义为海马型遗忘综合征。
  • 淀粉样蛋白β沉积状态通过18F-florbetapir PET评估,分为阳性和阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需更长随访以确定仅脑β-淀粉样蛋白沉积未预测30个月内进展为前驱期阿尔茨海默病这一发现是否保持一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improved understanding is needed of risk factors and markers of disease progression in preclinical Alzheimer's disease. We assessed associations between brain β-amyloidosis and various cognitive and neuroimaging parameters with progression of cognitive decline in individuals with preclinical Alzheimer's disease. METHODS: The INSIGHT-preAD is an ongoing single-centre observational study at the Salpêtrière Hospital, Paris, France. Eligible participants were age 70-85 years with subjective memory complaints but unimpaired cognition and memory (Mini-Mental State Examination [MMSE] score ≥27, Clinical Dementia Rating score 0, and Free and Cued Selective Reminding Test [FCSRT] total recall score ≥41). We stratified participants by brain amyloid β deposition on 18F-florbetapir PET (positive or negative) at baseline. All patients underwent baseline assessments of demographic, cognitive, and psychobehavioural, characteristics, APOE ε4 allele carrier status, brain structure and function on MRI, brain glucose-metabolism on 18F-fluorodeoxyglucose (18F-FDG) PET, and event-related potentials on electroencephalograms (EEGs). Actigraphy and CSF investigations were optional. Participants were followed up with clinical, cognitive, and psychobehavioural assessments every 6 months, neuropsychological assessments, EEG, and actigraphy every 12 months, and MRI, and 18F-FDG and 18F-florbetapir PET every 24 months. We assessed associations of amyloid β deposition status with test outcomes at baseline and 24 months, and with clinical status at 30 months. Progression to prodromal Alzheimer's disease was defined as an amnestic syndrome of the hippocampal type. FINDINGS: From May 25, 2013, to Jan 20, 2015, we enrolled 318 participants with a mean age of 76·0 years (SD 3·5). The mean baseline MMSE score was 28·67 (SD 0·96), and the mean level of education was high (score >6 [SD 2] on a scale of 1-8, where 1=infant school and 8=higher education). 88 (28%) of 318 participants showed amyloid β deposition and the remainder did not. The amyloid β subgroups did not differ for any psychobehavioural, cognitive, actigraphy, and structural and functional neuroimaging results after adjustment for age, sex, and level of education More participants positive for amyloid β deposition had the APOE ε4 allele (33 [38%] vs 29 [13%], p<0·0001). Amyloid β1-42 concentration in CSF significantly correlated with mean 18F-florbetapir uptake at baseline (r=-0·62, p<0·0001) and the ratio of amyloid β1-42 to amyloid β1-40 (r=-0·61, p<0·0001), and identified amyloid β deposition status with high accuracy (mean area under the curve values 0·89, 95% CI 0·80-0·98 and 0·84, 0·72-0·96, respectively). No difference was seen in MMSE (28·3 [SD 2·0] vs 28·9 [1·2], p=0·16) and Clinical Dementia Rating scores (0·06 [0·2] vs 0·05 [0·3]; p=0·79) at 30 months (n=274) between participants positive or negative for amyloid β. Four participants (all positive for amyloid β deposition at baseline) progressed to prodromal Alzheimer's disease. They were older than other participants positive for amyloid β deposition at baseline (mean 80·2 years [SD 4·1] vs 76·8 years [SD 3·4]) and had greater 18F-florbetapir uptake at baseline (mean standard uptake value ratio 1·46 [SD 0·16] vs 1·02 [SD 0·20]), and more were carriers of the APOE ε4 allele (three [75%] of four vs 33 [39%] of 83). They also had mild executive dysfunction at baseline (mean FCSRT free recall score 21·25 [SD 2·75] vs 29·08 [5·44] and Frontal Assessment Battery total score 13·25 [1·50] vs 16·05 [1·68]). INTERPRETATION: Brain β-amyloidosis alone did not predict progression to prodromal Alzheimer's disease within 30 months. Longer follow-up is needed to establish whether this finding remains consistent. FUNDING: Institut Hospitalo-Universitaire and Institut du Cerveau et de la Moelle Epinière (IHU-A-ICM), Ministry of Research, Fondation Plan Alzheimer, Pfizer, and Avid.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Dubois B, Epelbaum S, Nyasse F, et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018. PMID: 29500152. doi:10.1016/S1474-4422(18)30029-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。